Hemophagocytic Syndrome: An Unusual and Underestimated Complication of Cytoreduction Surgery with Heated Intraperitoneal Oxaliplatin

Schwarz, L.; Bridoux, Valérie; Veber, Benoît; Oksenhendler, Éric; Royon, Vincent; Michot, F; Tuech, Jean‐Jacques

doi:10.1245/s10434-013-3099-y

Cited by 9 publications

(1 citation statement)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One literature review includes 16 reports involving a total of 20 patients who were diagnosed with HLH secondary to a solid tumor (Table 2). Among the patients, 8 received immune checkpoint inhibitors (16)(17)(18)(20)(21)(22)(23)(24), 8 underwent chemotherapy (11)(12)(13)(14), and 4 were only diagnosed with a solid tumor (9,10,15,19). Thus, the application of immunotherapy as well as some HLH patients who are misdiagnosed as neoplastic fever may increase the incidence of HLH, which requires more attention.…”

Section: Epidemiologymentioning

confidence: 99%

Gastric cancer complicated with hemophagocytic lymphohistiocytosis: case report and a brief review

Zhou¹,

Cui²,

Yin³

et al. 2021

J Gastrointest Oncol

View full text Add to dashboard Cite

Hemophagocytic lymphohistiocytosis (HLH) comprises a group of severe immune function disorders that can lead to immune-mediated organ damage. There are two subtypes of HLH: primary and secondary. Secondary HLH is associated with infectious, oncologic, chemotherapeutic, and other underlying causes, and studies on HLH triggered by tumors have mainly focused on hematological malignancies.Secondary HLH in patients with solid tumors is rare. Here, we present two cases of gastric cancer complicated with HLH. The patient 1 was diagnosed as gastric cancer at stage I and got intractable fever after a distal subtotal gastrectomy without any evidence of infections or other complications. The patient 2 suffered from unresectable gastric adenocarcinoma and got fever, hemorrhagic rashes, and petechiae in mouth after six cycles of neoadjuvant chemotherapy. After detailed and comprehensive examinations, HLH was diagnosed in the two patients according to 2004 HLH diagnostic criteria, and the patients received treatment including immunosuppressive agents immediately. After therapy, the two patients showed partial remission, but both eventually died due to HLH relapse or progression of the primary tumor. The treatment regimen for HLH is intricate, and only a few relevant studies have focused on the treatment of cancer patients with HLH. The high mortality associated with this disease calls for more attention and additional research to improve the prognosis for these patients.

show abstract